中国能否诞生世界级生物医药企业？这些公司高管给出回答

Core Viewpoint - The Chinese biopharmaceutical industry is entering a new phase of accelerated development, with the potential to produce world-class companies, contingent on achieving certain performance metrics and core competencies in relevant fields [1][2]. Group 1: Conditions for Becoming World-Class Biopharmaceutical Companies - Chinese biopharmaceutical companies need to achieve sales of $1 billion to $2 billion from products developed in China to be considered world-class [2]. - Companies must possess core business capabilities and competitive advantages in their respective fields, with mergers and acquisitions being a necessary path to internationalization [3]. - Internationalization is crucial, as competing solely in the Chinese market is insufficient; companies must engage in global competition to demonstrate their core competencies [3]. Group 2: Challenges in International Expansion - The transition from optional to mandatory internationalization is a significant trend in the industry, with challenges including international environmental uncertainties and local protectionism [1][5]. - Companies face the challenge of achieving international recognition while navigating the complexities of the global market [5]. - The integration of AI in biopharmaceuticals is emerging as a trend, with applications in drug discovery and development, although it is primarily seen as a tool for efficiency rather than a revolutionary force [5][6]. Group 3: Perspectives on AI in Biopharmaceuticals - AI can assist in identifying drug targets and evaluating their viability, contributing to various stages of drug development and production [5]. - While AI enhances efficiency in foundational tasks, developing groundbreaking innovative drugs may still be challenging without significant data deployment [6].